




FIG. 1.




FIG. 2.




FIG. 3.




FIG. 4.




FIG. 5.




FIG. 6.





FIG. 7.



* p-value < 0.05, statistically significant difference versus vehicle (pilo 0%)

FIG. 8.





FIG. 9.



Participants will be randomized to receive Formulation 3 in either OD or OS and 1% commercial pilocarpine in the contralateral eye at Assessment 1. The same eye-treatment assignment will continue at Assessment 2, wherein Formulation 4 will replace Formulation 3.

Assessment 2 visit may be scheduled up to 6 months after Assessment 1 visit

FIG. 10.




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B